Seraph Awarded Patent for Alternative Method
(DETROIT) – Seraph Biosciences, Inc. (“Seraph”), creator of Seraspec®, is proud to announce it’s awarded patent for handheld micro-raman based methods of detection from the United States Patent and Trademark Office. Securing this patent sets the stage for future applications of the Seraspec® technology platform.
Seraspec® currently utilizes a disposable cuvette for specimen collection to help optimize traditional clinical service workflows. In addition to assisting clinicians, the newly-issued patent for “hand-held” applications of Seraspec® creates the possibility of leveraging the platform for a broader set of applications. Dr. Gregory Auner, Seraph’s Chief Science Officer, believes “patenting an alternative method for rapid and cost effective screening of bacteria, virus, and tissue abnormalities enables Seraph to focus beyond point-of-care clinical applications to methods deployable at any point-of-need”.
“This patent is the first of several in Seraph’s patent portfolio to issue. Written to protect applications important to population health, adaptable form factors like this could enable wider access to Seraspec®’s diagnostic technology,” said Braden Robison, Seraph’s Chief Operating Officer.
Dr. Gregory Auner is a co-founder and Chief Science Officer of Seraph Biosciences, Inc. Dr. Auner has over 30 patents (issued and pending) for chemical, biomedical, and environmental sensors and microsystems and has been granted more than $35 million in research grants and contracts as principal investigator.
Mr. Braden Robison is Chief Operating Officer of Seraph Biosciences, Inc. Mr. Robison brings over 18 years of experience in medical device commercialization and has launched more than 100 products through the FDA regulatory process.